Leyllane Rafael Moreira

Leyllane Rafael Moreira

Auto-generated profile, based on publicly available information

Leyllane Rafael Moreira

Universidade Federal de Pernambuco—UFPE Recife Pernambuco Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Experimental Parasitology
Verified
Journal Article
Closed access
CCCíntia Nascimento da Costa-Oliveira
Cíntia Nascimento da Costa-Oliveira
MPMilena Paiva-Cavalcanti
Milena Paiva-Cavalcanti
MBMichelle da Silva Barros
Michelle da Silva Barros
MNMineo Nakazawa
Mineo Nakazawa
MMMaria Gabriella Nunes de Melo
Maria Gabriella Nunes de Melo
VLVirginia Maria Barros de Lorena
Virginia Maria Barros de Lorena

17 April 2023 in Parasite Immunology
Verified
Journal Article
Closed access
LMLeyllane Rafael Moreira
Leyllane Rafael Moreira
KOKamila Kássia dos Santos Oliveira
Kamila Kássia dos Santos Oliveira
DTDiego José Lira Torres
Diego José Lira Torres
MBMichelle da Silva Barros
Michelle da Silva Barros
TATiago Ribeiro de Arruda
Tiago Ribeiro de Arruda
VLVirginia Maria Barros de Lorena
Virginia Maria Barros de Lorena

20 January 2023 in Natural Product Research
Verified
Journal Article
Closed access
JJJosé Noé da Silva Júnior
José Noé da Silva Júnior
ASAna Carla da Silva
Ana Carla da Silva
KOKamila Kássia dos Santos Oliveira
Kamila Kássia dos Santos Oliveira
LMLeyllane Rafael Moreira
Leyllane Rafael Moreira
SSSilvana Ferreira da Silva
Silvana Ferreira da Silva
APAna Lucia Figueiredo Porto
Ana Lucia Figueiredo Porto
Due to the limitations of Chagas disease therapy, microalgae can be promising in the search of new trypanocidal compounds, since these organisms produce bioactive compounds with large pharmaceutical applications, including antiparasitic effects. In this work, trypanocidal activity of aqueous extract of Tetradesmus obliquus and, for the first time, aqueous extract of Chlorella vulgaris, were evaluated against trypomastigote forms of Trypanosoma cruzi. In addition, cytotoxic activity in Vero cells was evaluated. Our results showed that C. vulgaris and T. obliquus present trypanocidal activity (IC50 = 32.9 µg ml−1 and 36.4 µg ml−1, respectively), however, C. vulgaris did not present cytotoxic effects in Vero cells (CC50 > 600 µg ml−1) and displayed a higher selectivity against trypomastigotes forms of T. cruzi (SI > 18). Thus, microalgae extracts, such as aqueous extract of C. vulgaris, are promising potential candidates for the development of natural antichagasic drugs. Graphical Abstract

22 February 2024 in Parasite Immunology
Verified
Journal Article
Closed access
DTDiego José Lira Torres
Diego José Lira Torres
KOKamila Kássia dos Santos Oliveira
Kamila Kássia dos Santos Oliveira
MBMichelle da Silva Barros
Michelle da Silva Barros
LMLeyllane Rafael Moreira
Leyllane Rafael Moreira
LFLuciane de Freitas Firmino
Luciane de Freitas Firmino
VLVirginia Maria Barros de Lorena
Virginia Maria Barros de Lorena

13 September 2024 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
KOKamila Kássia dos Santos Oliveira
Kamila Kássia dos Santos Oliveira
DTDiego José Lira Torres
Diego José Lira Torres
MBMichelle da Silva Barros
Michelle da Silva Barros
LMLeyllane Rafael Moreira
Leyllane Rafael Moreira
CJClaudeir Dias da Silva Junior
Claudeir Dias da Silva Junior
VLVirginia Maria Barros de Lorena
Virginia Maria Barros de Lorena
Introduction: Chagas disease is caused by the protozoan Trypanosoma cruzi and is clinically divided into acute and chronic phases. Chronic Chagas cardiomyopathy is the most studied manifestation of the disease. Vitamin D deficiency has been suggested as a risk factor for cardiovascular disease. No studies demonstrate the action of this hormone in the cells of patients with chronic Chagas heart disease.Objective: To evaluate the in vitro immunomodulatory effect of vitamin D on peripheral blood mononuclear cells of patients with the different chronic clinical forms of Chagas disease. Evaluating vitamin D's in vitro effect on blood cells by producing cytokines.Methods: Thirteen patients of the undetermined form (IND), 13 of the mild cardiac form (CARD1) and 14 of the severe cardiac form (CARD2) of Chagas disease, and 12 with idiopathic heart disease (CARDid) were included. The cells obtained from peripheral blood were treated in vitro with vitamin D (1 × 10−7 M) for 24 h and cytokines were dosed in the culture supernatant.Results: Although it was not possible to demonstrate statistically significant differences between the groups studied, our data showed that the cells treated with vitamin D modify (p < .05) the production of interferon‐γ (IFN‐γ) (decrease in IND), tumor necrosis factor‐α (TNF‐α) (decreased in CARD1 and CARDid), interleukin (IL)‐6 (increased in all groups), and IL‐10 (decreased in CARD1, CARD2, and CARDid) when compared to untreated cells.Conclusion: In vitro treatment with vitamin D distinctly modulated the production of cytokines by mononuclear cells of peripheral blood among patients with chronic and indeterminate cardiac clinical forms of Chagas disease.

1 January 2025 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
CSC D da Silva-Junior
C D da Silva-Junior
BSB A Silva
B A Silva
JGJ P Gonçales
J P Gonçales
MSM M da Silva
M M da Silva
LML R Moreira
L R Moreira
LML C R V Moura
L C R V Moura
Antiretroviral therapy (ART) is essential to reduce viral load and restore CD4+ T cell levels in people living with HIV/AIDS (PLWHA). However, different treatment protocols influence the levels of cytokines, important mediators of the immune response. This study aimed to evaluate cytokine levels in PLWHA on therapy with tenofovir (TDF), lamivudine (3TC), and dolutegravir (DTG). The results showed that PLWHA on treatment had a significant increase in CD4+ T lymphocyte levels and a reduction in CD8+ T lymphocyte levels compared to naive (untreated) individuals. Furthermore, PLWHA treated with TDF/3TC/DTG had a significant reduction in interleukin (IL)-4 and IL-10 levels (P<0.02; P=0.047) compared to other ART regimens. Naive individuals had higher levels of IL-2 and interferon (IFN)-γ, while their levels of tumor necrosis factor (TNF), IL-4, and IL-10 were lower. These findings suggested that TDF/3TC/DTG treatment modulated cytokines, reducing chronic inflammation and improving the immune response in PLWHA. The decrease in anti-inflammatory cytokines, such as IL-4 and IL-10, may be associated with better regulation of the immune system, resulting in greater control of infection and a balanced inflammatory response.